Non-viral and mRNA-based strategies for next-generation CAR-T cell therapy.
New non-viral methods to engineer CAR-T cells could make immunotherapy more accessible and easier to manufacture, potentially helping more patients access these treatments.
This review surveys non-viral and mRNA-based approaches to next-generation CAR-T cell therapy, which could overcome manufacturing barriers of current viral-vector methods. These strategies promise more accessible and potentially safer immunotherapies.
What the study was
- Study design
- Narrative review
- Population
- Cancer patients (conceptual)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Pathology, Research and Practice
Why it surfaced
Next-gen CAR-T manufacturing review. Relevant to accessibility and safety of immunotherapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.